Zurletrectinib is a brain-penetrant, orally active TRK inhibitor (TRKA IC50 = 0.81 nM, TRKB IC50 = 0.145 nM, TRKC IC50 = 0.184 nM). Zurletrectinib exhibits stronger activity as a consequence of its augmented binding affinity for TRK kinases. Zurletrectinib exhibits higher activity against most TRK inhibitor resistance mutations (13 out of 18 mutations). Zurletrectinib can be used for the study of glioma[1].
Molecular Weight:
415.40
Purity:
99.32
CAS Number:
[2403703-30-8]
Formula:
C19H19F2N7O2
Target:
c-Met/HGFR,Trk Receptor
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
